Revista de Investigación Científica y Tecnológica

Vol. 4 No. 1 (2020)
Artículos Originales

Bacteremia-causing agents in adult patients with febrile neutropenia at the Hospital de Clínicas. Paraguay

PDF (Español (España))
  • Víctor Daniel Giménez Ortigoza,
  • María Cristina San Miguel
Víctor Daniel Giménez Ortigoza
Universidad Nacional de Asunción, Paraguay
Bio
María Cristina San Miguel
Universidad Nacional de Asunción, Paraguay
Bio
DOI: https://doi.org/10.36003/Rev.investig.cient.tecnol.V4N1(2020)2

Published 2020-12-08

Keywords

  • Neutropenia,
  • bacteriemia,
  • hematología,
  • inmunosupresión
  • Neutropenia,
  • bacteremia,
  • hematology,
  • immunosuppression

How to Cite

Giménez Ortigoza, V. D., & San Miguel, M. C. (2020). Bacteremia-causing agents in adult patients with febrile neutropenia at the Hospital de Clínicas. Paraguay. Revista De Investigación Científica Y Tecnológica, 4(1), 21–29. https://doi.org/10.36003/Rev.investig.cient.tecnol.V4N1(2020)2

Copyright (c) 2020 Víctor Daniel Giménez Ortigoza, María Cristina San Miguel

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Febrile neutropenia is one of the most frequent complications with the highest morbidity and mortality in haematological patients. The changing trend in the etiology of bacteremia and the pattern of antimicrobial susceptibility compromise the response rate to empirical treatment regimens. The objective was to determine the frequency of isolated bacteria in patients with febrile neutropenia at the Hospital de Clínicas. The medical records of patients diagnosed with febrile neutropenia hospitalized in the 3 CCM in the HC-FCM from January 2016 to January 2019 were reviewed. The information was analyzed using Excell and Epiinfo. A total of 95 clinical records were reviewed, of which 72 met the criteria to be included in the present study. The average age of the patients was 38.63 ± 17.8 years, a 40% frequency of bacteremia, predominantly aetiological Gram-positive cocci, an average of 19.7 days of hospital stay. The most frequently isolated microbial species (klebsiella pneumoniae and Staphylococcus aureus).

PDF (Español (España))

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

  1. Ammann RA, Niggli FK, Leibundgut K, Teuffel O, Bodmer N. Exploring the association of hemoglobin level and adverse events in children with cancer presenting with fever in neutropenia. Plos one 2014; 9(7):e101696.
  2. Maguire JL, Kulik DM, Laupacis A. Kuppermann N, Uleryk EM, Parkin PC. Clinical prediction rules for children: a systematic review. Pediatrics 2011; 128:e666-677.
  3. Delebarre M, Marcher E, Mazingue F, Martinot A, Dubos F. Which decision rules meet methological standards in children with febrile neutropenia? Results of a systematic review and analysis. Pediatr Blood Cancer 2014; 61:1786-1791.
  4. Alp S, Akova M. Management of febrile neutropenia in the era of bacterial
  5. resistance. Ther Adv Infect Dis 2013; 1: 37-43.
  6. Bacteremia in hospitalized cancer patients with febrile neutropenia: a cohort study. Am J Infect Control 2014; 42: 74-6.
  7. Madrid C, Díaz L, Combariza J, Gálvez K, Olaya V, Ramírez I, Donado J. Epidemiología de la neutropenia febril en adultos con neoplasia hematológica, en un período de 26 meses en el Hospital Pablo Tobón Uribe, Colombia. Rev Chilena Infectol 2013; 30:195-201.
  8. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: e56-e92.
  9. Abou Saleh M, Ngozi Mafiana R, Al Za’abi M, Vaishnav R, Al Kindi S, Al- Zakwani I. Epidemiology of chemotherapy-induced neutropenia at a tertiary university hospital in Oman. Int J Clin Pharm 2013; 35: 1036-9.
  10. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353: 977-987.
  11. González-leal XJ, Molina-gamboa J, Bolaños-meade J, Villela L. Artículo original Aislamientos microbiológicos en pacientes con neutropenia febril. ¿Es apropiado el uso de las guías clínicas internacionales en México? Rev Hematol. 2013;14(81):113–9.
  12. Ting J. Neutropenia febril. Tratado Med urgencias pediátricas. 2007;(Iccm):320–1.
  13. Alp S, Akova M. Management of febrile neutropenia in the era of bacterial resistance. Ther Adv Infect Dis [Internet]. 2013 Feb [cited 2019 Mar 24];1(1):37–43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25165543
  14. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer : 2010 Update by the Infectious Diseases Society of America. 2011;52.
  15. Trucchia S, Edith R. Universidad Nacional De Córdoba Facultad De Ciencias Médicas Modelo Predictivo De Bacteriemia En Pacientes. 2015, (1):34–41.
  16. Daniel C, Silva B. Caracterizacion de la neutropenia febril en pacientes con leucemia linfoide aguda, tratados con quimioterapia de alto riesgo, atendidos en el instituto nacional de cancerologia desde 1 de enero al 31 de diciembre de 2008. 2009.
  17. Hinojosa L, Carpio D Del. Bacteriemia asociada a neutropenia febril en pacientes hemato-oncológicos, su espectro bacteriano y patrón de susceptibilidad antibiótica. Rev Med Hered. 2014; 25:22–9.
  18. Clínico H, Católica U, G RB, C IA, G GR, Garrido M, et al. Etiología de episodios de neutropenia febril en pacientes adultos con cáncer hematológico y de órganos sólidos en el Hospital Clínico Universidad Católica, Santiago-Chile. 2009;26(2):106–108.